Drug Insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women

@article{Colao2006DrugIC,
  title={Drug Insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women},
  author={Annamaria Colao and Antonella di Sarno and Ermelinda Guerra and Monica De Leo and Alberto Mentone and Gaetano Lombardi},
  journal={Nature Clinical Practice Endocrinology \&Metabolism},
  year={2006},
  volume={2},
  pages={200-210}
}
Prolactinoma is the most frequent pituitary tumor histotype. Men generally have macroadenomas whereas women generally have microadenomas. The major objectives of treating prolactinomas are to suppress excessive hormone secretion and its clinical consequences, to remove the tumor mass while preserving the residual pituitary function, and possibly to prevent disease recurrence or progression. Primary therapy of prolactinomas is based on use of dopamine-receptor agonists. Bromocriptine induces… 
Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas
TLDR
Data of this retrospective study demonstrate that cabergoline is an excellent option for the treatment of patients with bromocriptine-resistant IGPs.
Evaluation of therapy with cabergoline in men with macroprolactinoma
TLDR
The administration of cabergoline to patients with macroprolactinoma is effective in reaching PRL level nor‐ malisation as well as in tumour size reduction, and therapy with caberg Caroline led to remission of headaches, visual acuity correction, and a significant improvement in libido and erection in all patients.
Clinical management of difficult to treat macroprolactinomas
TLDR
The management of DA-resistant prolactinomas requires a multidisciplinary approach by an expert team and genetic screening for multiple endocrine neoplasia type 1 (MEN1) syndrome is actively discussed in a case-by-case approach.
Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review
TLDR
Based on analysis, CAB is significantly better than BRC in normalizing PRL levels in patients, especially males, with giant prolactinomas, and both drugs are comparably effective for patients of both genders.
Effect of dopaminergic drug treatment on surgical findings in prolactinomas
TLDR
It is found that patients exposed to BROM for at least 1 month are more likely to have tumor fibrosis than patients that are untreated or treated with CAB.
Efficacy and Cerebrospinal Fluid Rhinorrhea after Cabergoline Treatment in Patients with Bioactive Macroprolactinoma
TLDR
Predicting dopamine agonist resistance in patients with macroprolactinoma is essential for clinicians to prevent treatment failure and subsequent complications such as medication-induced cerebrospinal fluid (CSF) rhinorrhea and hypopituitarism was independently associated with an increased risk of cabergoline resistance and CSF rhinnorhea.
Physiological Study of Some Hormonal Parameters in Infertile Hyperprolactinemic Women in Pre and Post-Treatment with Cabergoline and Bromocriptine
TLDR
Hyperprolactinemia associated with increased and decreased in some hormonal parameters and the dopamine agonist agents are effective in correcting the disturbance in these parameters.
Prolactinoma: Diagnosis, Treatment, and Follow-up (A Review Article)
TLDR
Since misdiagnosis of prolactinoma can cause mistreatment with costly drugs, precise evaluation, accurate diagnosis, understanding indications of treatment, duration of treatment and follow up are of high importance.
Gender differences in macroprolactinomas: study of clinical features, outcome of patients and ki-67 expression in tumor tissue.
TLDR
This is the first study focused in macroprolactinomas that shows that they are clinically and biologically more aggressive in men, and testosterone could be a source for E2 in situ aromatization giving male tumors an advantage in cell proliferation.
The Chance of Permanent Cure for Micro- and Macroprolactinomas, Medication or Surgery? A Systematic Review and Meta-Analysis
TLDR
Patients with prolactinomas can consider transsphenoidal surgery as an alternative first-line treatment strategy after receiving primary surgical intervention and administration of DAs should be considered based on the postoperative PRL level to achieve the best long-term remission rate.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 87 REFERENCES
Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.
TLDR
This study demonstrates the effectiveness and minimal side effects of once-weekly cabergoline for treatment of macroprolactinomas, and during two further years of follow up, the improvement in PRL levels, gonadal function, and tumor size has persisted during Cabergoline administration, and three patients have experienced a further decline inPRL and/or tumor size.
Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
TLDR
The high efficacy and tolerability of cabergoline in the treatment of pathological hyperprolactinemia is confirmed, in a large-scale retrospective study, leaving few patients with unacceptable side effects or inadequate clinical response.
Primary medical therapy of micro- and macroprolactinomas in men.
TLDR
It is found that normalization of serum PRL levels occurs in approximately 80% of men with prolactinomas, and dopamine agonist administration yielded similar biochemical remission rates in men with microprolactinoma and macroprolACTinomas.
Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
TLDR
Recurrence rates two to five years after the withdrawal of cabergoline were 24 percent in patients with nontumoral hyperprolactinemia, 31 percent in Patients with micropr...
[Hyperprolactinemia in the male: clinical aspects and therapy].
TLDR
Investigation of male patients with hyperprolactinemia found that bromocriptine therapy led, in the majority of patients, not only to improvement of hypogonadal symptoms but also to normalization of PRL levels.
Prolactinomas in men: clinical characteristics and the effect of bromocriptine treatment.
TLDR
The study shows that the predominance of large tumours in men does not depend on patient's or doctor's delay, but on a high frequency of presumably rapidly growing PRL producing tumours, in the majority of patients, who do not give signs of hypogonadism before the tumour is revealed by local signs of tumour growth.
Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline
TLDR
In such macroprolactinomas the shrinkage of tumor is not strictly correlated with (or it is partially dissociated from) the inhibition of PRL hypersecretion, and the choice of other therapeutic options in cabergoline-resistant macroProlacti-nomas needs careful neuroradiological evaluation after a short trial of pharmacological treatment.
Hyperprolactinemia. Long-term effects of bromocriptine.
Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine.
TLDR
The effects of drug withdrawal and reinstitution on tumor size in two young men harboring large prolactinomas are described, finding that PRL levels rise again after withdrawal of bromocriptine therapy.
...
1
2
3
4
5
...